<?xml version="1.0" encoding="utf-8"?>
<!DOCTYPE trials [
<!ELEMENT trials (trial+)>

<!ELEMENT trial (main,contacts,countries,criteria,health_condition_code,health_condition_keyword,intervention_code,
          intervention_keyword,primary_outcome,secondary_outcome,secondary_sponsor,secondary_ids,source_support,ethics_reviews)>

<!ELEMENT main (trial_id,utrn?,reg_name,date_registration,primary_sponsor,public_title,acronym?,scientific_title,scientific_acronym?,
          date_enrolment,type_enrolment,target_size,recruitment_status,url?,study_type,study_design,phase,hc_freetext?,i_freetext?,results_actual_enrolment,results_date_completed,results_url_link,results_summary,           results_date_posted,results_date_first_publication,results_baseline_char,results_participant_flow,results_adverse_events,results_outcome_measures,results_url_protocol,results_IPD_plan, results_IPD_description)>
<!ELEMENT trial_id (#PCDATA)>
<!ELEMENT utrn (#PCDATA)>
<!ELEMENT reg_name (#PCDATA)>
<!ELEMENT date_registration (#PCDATA)><!-- dd/mm/yyyy -->
<!ELEMENT primary_sponsor (#PCDATA)>
<!ELEMENT public_title (#PCDATA)>
<!ELEMENT acronym (#PCDATA)>
<!ELEMENT scientific_title (#PCDATA)>
<!ELEMENT scientific_acronym (#PCDATA)>
<!ELEMENT date_enrolment (#PCDATA)><!-- dd/mm/yyyy -->
<!ELEMENT type_enrolment (#PCDATA)>
<!ELEMENT target_size (#PCDATA)>
<!ELEMENT recruitment_status (#PCDATA)><!-- Pending,Recruiting,Suspended,Complete,Other -->
<!ELEMENT url (#PCDATA)>
<!ELEMENT study_type (#PCDATA)><!-- interventional,observational -->
<!ELEMENT study_design (#PCDATA)>
<!ELEMENT phase (#PCDATA)>
<!ELEMENT hc_freetext (#PCDATA)>
<!ELEMENT i_freetext (#PCDATA)>
<!ELEMENT results_actual_enrolment (#PCDATA)>
<!ELEMENT results_date_completed (#PCDATA)><!-- dd/mm/yyyy -->
<!ELEMENT results_url_link (#PCDATA)>
<!ELEMENT results_summary (#PCDATA)>
<!ELEMENT results_date_posted (#PCDATA)><!-- dd/mm/yyyy -->
<!ELEMENT results_date_first_publication (#PCDATA)><!-- dd/mm/yyyy -->
<!ELEMENT results_baseline_char (#PCDATA)>
<!ELEMENT results_participant_flow (#PCDATA)>
<!ELEMENT results_adverse_events (#PCDATA)>
<!ELEMENT results_outcome_measures (#PCDATA)>
<!ELEMENT results_url_protocol (#PCDATA)>
<!ELEMENT results_IPD_plan (#PCDATA)>
<!ELEMENT results_IPD_description (#PCDATA)>


<!ELEMENT contacts (contact+)>
<!ELEMENT contact (type,firstname,middlename,lastname,address,city,country1,zip,telephone,email,affiliation)>
<!ELEMENT type (#PCDATA)><!-- Public,Scientific -->
<!ELEMENT firstname (#PCDATA)>
<!ELEMENT middlename (#PCDATA)>
<!ELEMENT lastname (#PCDATA)>
<!ELEMENT address (#PCDATA)>
<!ELEMENT city (#PCDATA)>
<!ELEMENT country1 (#PCDATA)>
<!ELEMENT zip (#PCDATA)>
<!ELEMENT telephone (#PCDATA)>
<!ELEMENT email (#PCDATA)>
<!ELEMENT affiliation (#PCDATA)>

<!ELEMENT countries (country2+)>
<!ELEMENT country2 (#PCDATA)>

<!ELEMENT criteria (inclusion_criteria,agemin,agemax,gender,exclusion_criteria)>
<!ELEMENT inclusion_criteria (#PCDATA)>
<!ELEMENT agemin (#PCDATA)>
<!ELEMENT agemax (#PCDATA)>
<!ELEMENT gender (#PCDATA)>
<!ELEMENT exclusion_criteria (#PCDATA)>

<!ELEMENT health_condition_code (hc_code+)>
<!ELEMENT hc_code (#PCDATA)>

<!ELEMENT health_condition_keyword (hc_keyword+)>
<!ELEMENT hc_keyword (#PCDATA)>

<!ELEMENT intervention_code (i_code+)>
<!ELEMENT i_code (#PCDATA)>

<!ELEMENT intervention_keyword (i_keyword+)>
<!ELEMENT i_keyword (#PCDATA)>

<!ELEMENT primary_outcome (prim_outcome+)>
<!ELEMENT prim_outcome (#PCDATA)>

<!ELEMENT secondary_outcome (sec_outcome+)>
<!ELEMENT sec_outcome (#PCDATA)>

<!ELEMENT secondary_sponsor (sponsor_name+)>
<!ELEMENT sponsor_name (#PCDATA)>

<!ELEMENT secondary_ids (secondary_id+)>
<!ELEMENT secondary_id (sec_id,issuing_authority)>
<!ELEMENT sec_id (#PCDATA)>
<!ELEMENT issuing_authority (#PCDATA)>

<!ELEMENT source_support (source_name+)>
<!ELEMENT source_name (#PCDATA)>

<!ELEMENT ethics_reviews (ethics_review+)>
<!ELEMENT ethics_review (status,approval_date,contact_name,contact_address,contact_phone,contact_email)>
<!ELEMENT status (#PCDATA)><!-- Not approved,Approved,NA -->
<!ELEMENT approval_date (#PCDATA)><!-- dd/mm/yyyy -->
<!ELEMENT contact_name (#PCDATA)>
<!ELEMENT contact_address (#PCDATA)>
<!ELEMENT contact_phone (#PCDATA)>
<!ELEMENT contact_email (#PCDATA)>
]>
<trials>
  <trial>
    <main>
      <trial_id>IRCT20210405050851N1</trial_id>
      <utrn></utrn>
      <reg_name>IRCT</reg_name>
      <date_registration>2021-10-30</date_registration>
      <primary_sponsor>Iran University of Medical Sciences</primary_sponsor>
      <public_title>Comparing of programmed intermittent epidural bolus with continuous epidural infusion for labor analgesia</public_title>
      <acronym></acronym>
      <scientific_title>Comparing of programmed intermittent epidural bolus (PIEB) with continuous epidural infusion (CEI) for labor analgesia in patients receiving epidural dexmedetomidine and Rupivacaine</scientific_title>
      <scientific_acronym></scientific_acronym>
      <date_enrolment>2021-11-06</date_enrolment>
      <type_enrolment>anticipated</type_enrolment>
      <target_size>60</target_size>
      <recruitment_status>Complete</recruitment_status>
      <url>https://irct.ir/trial/57447</url>
      <study_type>interventional</study_type>
      <study_design>Randomization: Randomized, Blinding: Double blinded, Placebo: Not used, Assignment: Parallel, Purpose: Treatment, Randomization description: Patients will be randomly assigned to tree groups by using a random number table. In order to randomize, a random block method will be used. For this purpose, we formed blocks of size 6. In each block, 3 individuals will be in first intervention group and 3 will be in second intervention group. A total of 10 blocks will be considered for the study, Blinding description: Surgeons and patients will be kept blind and unaware of the type of labor analgesia . Patients will be aware that they will be randomly assigned to one of two treatment groups, but will be unaware of which analgesic method  will be provided in that group. Patients will be assigned to one of two groups using random number tables. The surgeon also knows that patients will be anesthetized in two different ways, but will not know which procedure will be performed for each patient. The data collection officer, analyst and outcome assessor  will collect and analyze information based on groups 1 and 2 and will not be aware of the type of type of analgesia presented in the groups. They will be kept blind.</study_design>
      <phase>2-3</phase>
      <hc_freetext>Epidural labor analgesia.</hc_freetext>
      <i_freetext>Intervention 1: Intervention group 1: Term women with gestational age 37 weeks or more who have entrance condition to the study, amount of 3cc test dose of Dexmedetomidine 0.5µg/ml and Rupivacain %0.1 will be administered and after 5 minutes, amount of 8cc from the same solution as loading dose will be administered. then in the group programmed intermittent epidural bolus, bolus dose of 8cc of the solution will be administered every 60 minutes regularly. Intervention 2: Intervention group 2: Term women with gestational age 37 weeks or more who have entrance condition to the study, amount of 3cc test dose of Dexmedetomidine 0.5µg/ml and Rupivacain %0.1 will be administered and after 5 minutes, amount of 8cc from the same solution as loading dose will be administered. in the continuous epidural infusion group, infusion of 8 cc/hr of the solution consumption as maintenance after loading dose will be administered continuously by an infusion pomp.</i_freetext>
      <results_actual_enrolment></results_actual_enrolment>
      <results_date_completed></results_date_completed>
      <results_url_link></results_url_link>
      <results_summary></results_summary>
      <results_date_posted></results_date_posted>
      <results_date_first_publication></results_date_first_publication>
      <results_baseline_char></results_baseline_char>
      <results_participant_flow></results_participant_flow>
      <results_adverse_events></results_adverse_events>
      <results_outcome_measures></results_outcome_measures>
      <results_url_protocol></results_url_protocol>
      <results_IPD_plan>Undecided - It is not yet known if there will be a plan to make this available</results_IPD_plan>
      <results_IPD_description>Justification or reason for indecision in sharing IPD is After completing the work and consulting with all the writers and executive agents, I will be decided.</results_IPD_description>
    </main>
    <contacts>
      <contact>
        <type>public</type>
        <firstname>Golnoosh Khosravian</firstname>
        <middlename></middlename>
        <lastname></lastname>
        <address>No. 2, Dead end Aghaghia., South Makouyipour Ave., Behzadi Ave.,13th East Velenjak Ave</address>
        <city>Tehran</city>
        <country1>Iran (Islamic Republic of)</country1>
        <zip>1987733373</zip>
        <telephone>+98 21 2243 4717</telephone>
        <email>desdemona_wsh@yahoo.com</email>
        <affiliation>Iran University of Medical Sciences</affiliation>
      </contact>
      <contact>
        <type>scientific</type>
        <firstname>Golnoosh Khosravian</firstname>
        <middlename></middlename>
        <lastname></lastname>
        <address>No. 2, Dead end Aghaghia., South Makouyi pour Ave., Behzadi Ave., 13thEast Velenjak Ave</address>
        <city>Tehran</city>
        <country1>Iran (Islamic Republic of)</country1>
        <zip>1987733373</zip>
        <telephone>+98 21 2243 4717</telephone>
        <email>desdemona_wsh@yahoo.com</email>
        <affiliation>Iran University of Medical Sciences</affiliation>
      </contact>
    </contacts>
    <countries>
      <country2>Iran (Islamic Republic of)</country2>
    </countries>
    <criteria>
      <inclusion_criteria>Term woman with gestational age 37 weeks or more
Cervical dilation Larger than 4 cm
Spontaneous or induced labor pain
Applying for epidural analgesia
Weight 55 to 85 kg</inclusion_criteria>
      <agemin>18 years</agemin>
      <agemax>45 years</agemax>
      <gender>Female</gender>
      <exclusion_criteria>Patients with past medical history of sever cardiovascular diseases and bradycardia
Contraindication of epidural analgesia
Patients that are candidate for cesarean section ( multiple pregnancy , gestational age more than 37 weeks, preeclampsia , etc )
Patient discontent
Opium addiction
Height less than 150 cm</exclusion_criteria>
    </criteria>
    <health_condition_code>
      <hc_code>O74.6</hc_code>
    </health_condition_code>
    <health_condition_keyword>
      <hc_keyword>Other complications of spinal and epidural anesthesia during labor and delivery</hc_keyword>
    </health_condition_keyword>
    <intervention_code>
      <i_code>Treatment - Drugs</i_code>
      <i_code>Treatment - Drugs</i_code>
    </intervention_code>
    <intervention_keyword>
      <i_keyword>Intervention group 1: Term women with gestational age 37 weeks or more who have entrance condition to the study, amount of 3cc test dose of Dexmedetomidine 0.5µg/ml and Rupivacain %0.1 will be administered and after 5 minutes, amount of 8cc from the same solution as loading dose will be administered. then in the group programmed intermittent epidural bolus, bolus dose of 8cc of the solution will be administered every 60 minutes regularly.</i_keyword>
      <i_keyword>Intervention group 2: Term women with gestational age 37 weeks or more who have entrance condition to the study, amount of 3cc test dose of Dexmedetomidine 0.5µg/ml and Rupivacain %0.1 will be administered and after 5 minutes, amount of 8cc from the same solution as loading dose will be administered. in the continuous epidural infusion group, infusion of 8 cc/hr of the solution consumption as maintenance after loading dose will be administered continuously by an infusion pomp.</i_keyword>
    </intervention_keyword>
    <primary_outcome>
      <prim_outcome>Maternal satisfaction of labor analgesia. Timepoint: At the end of labor. Method of measurement: Visual analogue scale.</prim_outcome>
      <prim_outcome>Total dose of Dexmedetomidine using in the end of labor. Timepoint: At the end of labor. Method of measurement: Based on checklist - in milliliters.</prim_outcome>
      <prim_outcome>Total dose of Rupivacain using in the end of labor. Timepoint: At the end of labor. Method of measurement: Based on checklist - in milliliters.</prim_outcome>
    </primary_outcome>
    <secondary_outcome>
      <sec_outcome>New born Infant Apgar score. Timepoint: In the first and fifth minute after fetal delivery. Method of measurement: Apgar score.</sec_outcome>
      <sec_outcome>Infant Arterial Blood Gas. Timepoint: Five minutes after fetal delivery. Method of measurement: Umbilical cord arterial blood.</sec_outcome>
      <sec_outcome>Incidence rate of instrumental delivery. Timepoint: The last stage of delivery. Method of measurement: Record in the end of labor.</sec_outcome>
      <sec_outcome>Duration of delivery. Timepoint: Duration of delivery from the time of patient entrance in the labor until the time of fetal delivery. Method of measurement: Based on checklist - minute unit.</sec_outcome>
      <sec_outcome>Side effects including nausea, vomiting, itching, decrease blood pressure, bradycardia. Timepoint: From the loading dose of epidural analgesia every hour till the end of labor. Method of measurement: Patient's sign and symptoms and record in the checklist.</sec_outcome>
      <sec_outcome>Incidence rate of motor block. Timepoint: From the beginning of Epidural analgesia every hour till the end of labor. Method of measurement: Bromage score (0- 1- 2- 3).</sec_outcome>
    </secondary_outcome>
    <secondary_sponsor>
      <sponsor_name></sponsor_name>
    </secondary_sponsor>
    <secondary_ids>
      <secondary_id>
        <sec_id></sec_id>
        <issuing_authority></issuing_authority>
      </secondary_id>
    </secondary_ids>
    <source_support>
      <source_name>Iran University of Medical Sciences</source_name>
    </source_support>
    <ethics_reviews>
      <ethics_review>
        <status>Approved</status>
        <approval_date>2020-09-19</approval_date>
        <contact_name>Ethics committee of Iran University of Medical Science</contact_name>
        <contact_address>Iran University of Medical Sciences, Hemmat Highway Tehran Tehran Iran (Islamic Republic of)</contact_address>
        <contact_phone></contact_phone>
        <contact_email></contact_email>
      </ethics_review>
    </ethics_reviews>
  </trial>
</trials>
